RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF MAY 5, 2016 BY AND BETWEEN THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA AND DIMENSION THERAPEUTICS, INC.Research, Collaboration & License Agreement • February 21st, 2018 • Ultragenyx Pharmaceutical Inc. • Pharmaceutical preparations • Pennsylvania
This Research, Collaboration & License Agreement (this “Agreement”) is dated as of May 5, 2016 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Dimension Therapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
RESEARCH COLLABORATION LICENSE AGREEMENT BY AND BETWEEN EMISPHERE TECHNOLOGIES, INC. AND NOVARTIS PHARMA AGResearch Collaboration License Agreement • March 30th, 2005 • Emisphere Technologies Inc • Pharmaceutical preparations • New York
This Research Collaboration License Agreement (the “Agreement”), dated and effective as of September __, 2004 (the “Effective Date”) is between Emisphere Technologies, Inc., a Delaware corporation with offices at 765 Old Saw Mill River Road, Tarrytown, New York 10591, USA (“Emisphere”), and Novartis Pharma AG, a company registered in Switzerland with offices at Lichtstrasse 35, CH 4056 Basel, Switzerland (“Novartis”) and Novartis and Emisphere shall each be a “Party” and together the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED. RESEARCH, COLLABORATION & LICENSE AGREEMENT...Research, Collaboration & License Agreement • February 3rd, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Research, Collaboration & License Agreement (this “Agreement”) is dated as of September 18, 2018 (the “Effective Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF MAY 28, 2019Research, Collaboration & License Agreement • August 8th, 2019 • Amicus Therapeutics, Inc. • Pharmaceutical preparations • Pennsylvania
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT PASSAGE BIO, INC. TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDED AND RESTATED RESEARCH, COLLABORATION &...Research, Collaboration & License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Second Amended and Restated Research, Collaboration & License Agreement (this “Agreement”) is effective as of July 31, 2024 (the “Second Restatement Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
Certain information has been excluded from this agreement (indicated by “[***]”) because Taysha Gene Therapies, Inc. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. RESEARCH,...Research, Collaboration & License Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances) • Texas
This Research, Collaboration & License Agreement (this “Agreement”) is dated as of November 19, 2019 (the “Effective Date”) by and between The Board of Regents of the University of Texas System (“System”), an agency of the State of Texas, on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System (“Licensor”), and Taysha Gene Therapies, Inc. a corporation organized under the laws of the state of Texas (“Licensee”). Licensor and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
RESEARCH, COLLABORATION & LICENSE AGREEMENT DATED AS OF July 31, 2024 BY AND BETWEEN GEMMA BIOTHERAPEUTICS, INC. AND PASSAGE BIO, INC.Research, Collaboration & License Agreement • November 13th, 2024 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Research, Collaboration & License Agreement (this “Agreement”) is effective as of July 31, 2024 (“Effective Date”) by and between Gemma Biotherapeutics, Inc., a corporation organized under the laws of the state of Delaware (“Gemma”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Passage”). Gemma and Passage may be referred to herein as a “Party” or, collectively, as “Parties”.
Certain information has been excluded from this agreement (indicated by “[***]”) because Taysha Gene Therapies, Inc. has determined such information (i) is not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT TO...Research, Collaboration & License Agreement • September 2nd, 2020 • Taysha Gene Therapies, Inc. • Biological products, (no disgnostic substances)
This Amendment to the November 19, 2019 Research, Collaboration & License Agreement (“Amendment”) is entered into as of April 2, 2020 (the “Amendment Effective Date”) by and between The Board of Regents (“Board”) of The University of Texas System (“System”), an agency of the State of Texas whose address is 210 West 7th Street, Austin, Texas 78701, on behalf of The University of Texas Southwestern Medical Center (“UT Southwestern”), a component institution of System (“Licensor”), and Taysha Gene Therapies, Inc., a Texas corporation (“Licensee”). Licensor and Licensee are referred to collectively as the “Parties” and individually as a “Party”. All capitalized terms used but not defined herein shall have the meaning ascribed to such term in the Agreement.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED. AMENDED AND RESTATED RESEARCH, COLLABORATION &...Research, Collaboration & License Agreement • August 13th, 2020 • Passage BIO, Inc. • Biological products, (no disgnostic substances) • Pennsylvania
This Amended and Restated Research, Collaboration & License Agreement (this “Agreement”) is effective as of September 18, 2018 (“Effective Date”), and is restated as of May 5, 2020 (the “Restatement Date”) by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”.
RESEARCH COLLABORATION LICENSE AGREEMENT BY AND BETWEEN EMISPHERE TECHNOLOGIES, INC. AND NOVARTIS PHARMA AGResearch Collaboration License Agreement • October 13th, 2004 • Emisphere Technologies Inc • Pharmaceutical preparations • New York
This Research Collaboration License Agreement (the “Agreement”), dated and effective as of September __, 2004 (the “Effective Date”) is between Emisphere Technologies, Inc., a Delaware corporation with offices at 765 Old Saw Mill River Road, Tarrytown, New York 10591, USA (“Emisphere”), and Novartis Pharma AG, a company registered in Switzerland with offices at Lichtstrasse 35, CH 4056 Basel, Switzerland (“Novartis”) and Novartis and Emisphere shall each be a “Party” and together the “Parties”.
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO PASSAGE BIO, INC. IF PUBLICLY DISCLOSED. FIFTH AMENDMENT TO AMENDED AND RESTATED...Research, Collaboration & License Agreement • November 4th, 2021 • Passage BIO, Inc. • Biological products, (no disgnostic substances)
This Fifth Amendment (“Fifth Amendment”) is effective as of August 3, 2021 (“Fifth Amendment Effective Date”) to amend the Amended and Restated Research, Collaboration & License Agreement, as amended to date (the “Agreement”) entered into as of May 5, 2020 by and between The Trustees of the University of Pennsylvania, a Pennsylvania nonprofit corporation (“Penn”), and Passage Bio, Inc., a corporation organized under the laws of the state of Delaware (“Licensee”). Penn and Licensee may be referred to herein as a “Party” or, collectively, as “Parties”. Capitalized terms that are used but not defined herein shall have the meanings ascribed to such terms in the Agreement.
